Friulimicin B

• CAT Number: I027798
• CAS Number: 239802-15-4
• Molecular Formula: C59H94N14O19
• Molecular Weight: 1303.48
• Purity: 98%
• Synonyms: Friulimicin B
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (2S)-2-[(3S,4S,7S,13S,16R,22S,28S,31S,34R)-16-[(1R)-1-aminoethyl]-3-[[(2S)-4-amino-2-[[(Z)-12-methyltridec-3-enoyl]amino]-4-oxobutanoyl]amino]-22,28-bis(carboxymethyl)-4-methyl-2,6,12,15,18,21,24,27,30,33-decaoxo-13-propan-2-yl-1,5,11,14,17,20,23,26,29,32-decazatricyclo[32.4.0.07,11]octatriacontan-31-yl]propanoic acid
• InChI: InChI=1S/C59H94N14O19/c1-30(2)19-14-12-10-8-9-11-13-15-22-41(75)65-35(25-40(61)74)52(84)71-49-34(7)64-53(85)39-21-18-24-73(39)57(89)46(31(3)4)69-56(88)48(33(6)60)68-43(77)29-63-50(82)36(26-44(78)79)66-42(76)28-62-51(83)37(27-45(80)81)67-55(87)47(32(5)59(91)92)70-54(86)38-20-16-17-23-72(38)58(49)90/h13,15,30-39,46-49H,8-12,14,16-29,60H2,1-7H3,(H2,61,74)(H,62,83)(H,63,82)(H,64,85)(H,65,75)(H,66,76)(H,67,87)(H,68,77)(H,69,88)(H,70,86)(H,71,84)(H,78,79)(H,80,81)(H,91,92)/b15-13-/t32-,33+,34-,35-,36-,37-,38+,39-,46-,47-,48+,49-/m0/s1
• InChIKey: HVYFVLAUKMGKHL-USKUEUQVSA-N
• SMILES: C1(=O)[C@@H](NC(=O)[C@H](CC(=O)N)NC(=O)C/C=CCCCCCCCC(C)C)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3N1CCCC3)[C@@H](C(=O)O)C)CC(=O)O)CC(=O)O)[C@H](N)C)[C@@H](C)C)CCC2)C

Friulimicin B(CAT: I027798) is a cyclic lipopeptide antibiotic derived from Actinoplanes friuliensis. It exhibits strong activity against Gram-positive bacteria, including drug-resistant strains like MRSA. Friulimicin B disrupts bacterial cell wall biosynthesis by targeting peptidoglycan precursor synthesis, a crucial step for bacterial survival. This unique mechanism makes it a promising candidate in antibiotic and infectious disease research, particularly for combating multi-drug-resistant pathogens. Its potential as a novel antimicrobial agent addresses the urgent need for new treatments in the face of rising antibiotic resistance. Friulimicin B also serves as a valuable tool for studying bacterial cell wall biosynthesis and resistance mechanisms.